|Bid||64.10 x 900|
|Ask||69.25 x 800|
|Day's range||65.54 - 68.16|
|52-week range||21.06 - 79.65|
|Beta (5Y monthly)||0.37|
|PE ratio (TTM)||N/A|
|Earnings date||04 May 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||92.10|
DUBLIN, May 16, 2023--Prothena announced today the appointment of Dr. Billy Dunn, the founding Director of the Office of Neuroscience, CDER, to its Board of Directors.
Prothena (PRTA) reports a wider loss in the first quarter. The company makes considerable pipeline progress.
Prothena (PRTA) delivered earnings and revenue surprises of -7.23% and 85.51%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
DUBLIN, May 04, 2023--Prothena today reported financial results for the first quarter of 2023 and provided business highlights.
DUBLIN, April 27, 2023--Prothena today announced that it will report its first quarter 2023 financial results on Thursday, May 4, 2023.
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DUBLIN, April 24, 2023--Prothena today announced that members of its management team will participate in a fireside chat at the 2023 Bank of America Healthcare Conference.
Walgreens (WBA) collaborates with Prothena Corporation to support patient awareness, participation and representation in a clinical trial of Prothena's Alzheimer's drug candidate, PRX012.
DEERFIELD, Ill. & DUBLIN, April 13, 2023--Walgreens and Prothena today announced a collaboration to accelerate patient identification and recruitment for Prothena’s ongoing ASCENT-2 multiple ascending dose clinical trial evaluating the safety and tolerability of PRX012, a potential best-in-class anti-amyloid beta antibody under development for the treatment of Alzheimer’s disease. As part of the collaboration, Walgreens will leverage its national footprint, portfolio of industry-leading healthca
Prothena (PRTA) surges 29% in the past one year as investors are optimistic on its promising Alzheimer's Disease pipeline.
DUBLIN, March 31, 2023--Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023
DUBLIN, Ireland, March 21, 2023--Prothena announced today that members of its senior management team will participate in a fireside chat at Stifel 2023 Virtual CNS Days on March 28 .
DUBLIN, March 14, 2023--Prothena announced broad participation at AD/PD 2023 highlighting leadership in advancing treatments for Alzheimer’s and Parkinson’s disease
Prothena (PRTA) reports better-than-expected results for the fourth quarter. The company makes considerable pipeline progress.
DUBLIN, February 23, 2023--Prothena Corporation plc today reported financial results for the 4th quarter and full year 2022.
DUBLIN, February 16, 2023--Prothena Corporation plc announced that it will report its fourth quarter and full year 2022 financial results on February 23, 2023.
DUBLIN, February 03, 2023--Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, January 31, 2023--Prothena announced positive topline Phase 1 SAD study results for PRX005, an investigational tau antibody for the treatment of Alzheimer’s disease.
DUBLIN, December 15, 2022--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it priced an underwritten public offering of 3,250,000 of its ordinary shares at a price to the public of $56.50 per ordinary share, before the underwriting discount and estimated offering expenses. All of the ordinary shares in the offering were sold by Prothena. In add
DUBLIN, December 13, 2022--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it has commenced an underwritten public offering of 3,000,000 of its ordinary shares. All of the ordinary shares in the offering will be sold by Prothena. In addition, Prothena expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the n
DUBLIN, December 12, 2022--Prothena presented data from phase 3 VITAL study observing a statistically significant survival benefit in patients with Mayo Stage IV AL amyloidosis.
Investor confidence in Biogen (BIIB) is rattled following reports of a study participant's death who was administered its Alzheimer's disease (AD) antibody in clinical studies.
Prothena (PRTA) earns a $40 million milestone payment from Novo Nordisk following the progress of NNC6019 in a phase II study for the treatment of ATTR cardiomyopathy.
DUBLIN, November 21, 2022--Prothena announced that it has earned a $40 million milestone payment from Novo Nordisk.
Prothena (PRTA) incurs a loss in the third quarter while revenues miss estimates.